Trane Technologies (TT) Q2 2026 (USD): Revenue 6.35bln (exp. 6.2bln), adj. EPS 4.31 (exp. 4.27)
Newsquawk Staff ·
- adj. EBITDA 1.34bln (exp. 1.35bln).
What it means
A mixed print of this shape, top-line and per-share earnings ahead of consensus with adjusted EBITDA a touch light, has historically produced muted reactions in the capital goods complex: the headline beat draws the initial move, but the margin line tends to set the intraday direction once the call begins, since EBITDA is where input cost pass-through and price/cost dynamics actually show up for HVAC and building products names. The recurring question on prints like this is whether the revenue beat is volume or price, and whether the shortfall against the EBITDA consensus reflects tariff-related cost, mix, or investment timing, each of which carries a different read-through for full-year guidance. Trane has tended to be treated as a quality compounder in the sector, so guidance and the bookings and backlog commentary, particularly in commercial HVAC and transport refrigeration, matter more than the quarter itself. Worth noting are the follow-ons: any revision to full-year revenue and margin ranges on the call, and whether peers in building products and climate equipment trade in sympathy, as sympathy moves have been the established pattern when the miss sits in the margin line rather than demand. The multi-region tag footprint reflects Trane's meaningful non-US revenue exposure, where FX translation has been a recurring swing factor in reported figures.
- US President Trump on Iran, says may do it a little bit further
- US President Trump, on Ukraine’s Starlink (SPCX) access, says it’s a very interesting situation; won’t comment on whether he spoke to Elon Musk; bottom line is Musk put it back
- CRUDE WRAP: WTI (Z6) SETTLES USD 2.32 HIGHER AT 99.47/BBL; BRENT (Z6) SETTLES USD 4.35 HIGHER AT USD 113.17/BBL
- Ukraine President Zelensky says Ukraine is ready for peace talks at G20, but so far no such invitation
- An Israeli military official told Channel 12 that here is no reason to launch an attack on Iran before the elections; If we detect preparations in Iran for an attack, we will act
Related headlines
- US President Trump invokes Section 232 on wind turbine imports2 hours ago
- US President Trump signs EO on housing costs, aiming to cut mortgage insurance premiums2 hours ago
- US President Trump called Musk and asked him to lift Ukraine Starlink (SPCX) restrictions, WSJ reports3 hours ago
- US President Trump says "Iran is doing everything they can to drive up the price of Oil prior to the U.S. Midterm Election". 6 hours ago
- Infineum is exploring a USD 8bln sale, the FT reports8 hours ago
- OpenAI is raising up to USD 30bln in funding round at a USD 1.25tln valuation, led by UAE investors, according to CNBC, citing sources; OpenAI is negotiating a commercial deal that would secure more computing capacity from the UAE1 hour ago
- Western Digital (WDC) Q1 2027 (USD): Adj. EPS 4.64 (exp. 4.08), Revenue 4.38bln (exp. 4.14bln)1 hour ago
- US EQUITY OPEN: Mag-7 earnings lead Tech and Indices lower as the Middle East situation remains fragile7 hours ago
- Money markets no longer full price a Fed rate hike before end of 20264 hours ago
- [Market Update] Risk-off trade continues as AI concerns linger; stocks trade at new lows with NQ -3.0% as tech leads losses, while gold sees new lows; Treasuries push to new highs, weighing on USD; oil trades off highs supported by geopolitical risk3 hours ago
- Bloom Energy (BE) Q3 2026 (USD): Adj. EPS 0.94 (exp. 0.69), Revenue 1.24bln (exp. 1.06bln)1 hour ago
- Elon Musk makes USD 1bln investment in Skydance (SKYD), Semafor reports5 hours ago
- Newsquawk Daily US Earnings Estimates - 23rd October 2026: AXP5 hours ago
- A US source told Al Arabiya that the Florida meetings between Lebanon and Israel ended without a breakthrough3 hours ago
- Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone3 hours ago